|
Medical Education Partnership Initiative (MEPI)
|
Training Initiative
|
CDC, HRSA
|
FIC, NCI, NHGRI, NHLBI, NIMH, NINDS, NINR, OD/DPCPSI/OAR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC
|
The Medical Education Partnership Initiative (MEPI) is intended to build human capacity for health in Africa by strengthening the medical education system in an environment that values and nurtures research in President''s Emergency Plan for AIDS Relief (PEPFAR)-funded countries. This program also works to build clinical and research capacity in Africa as part of a retention strategy for faculty of medical schools and clinical professors. Administered by FIC/NIH, MEPI works in collaboration with OGAC, HRSA, USAID, DOD, Peace Corps, African Ministries of Health, as well as international agencies, including the World Health Organization, World Bank, and Welcome Trust.
|
|
Medical Expenditure Panel Survey (MEPS)
|
Health Survey
|
AHRQ
|
NCI
|
The Medical Expenditure Panel Survey (MEPS) is a set of large-scale surveys of families and individuals, their medical providers, and employers across the United States. MEPS is the most complete source of data on the cost and use of health care and health insurance coverage.
|
|
Medicare Benefit Postcard
|
Public Education Campaign
|
CMS
|
NEI
|
The National Eye Institute (NEI) worked with the Centers for Medicare and Medicaid Services (CMS) to develop and disseminate a Medicare benefit card in English and Spanish which describes eligibility for the Medicare benefit for glaucoma and diabetic eye disease. The postcards are distributed to Medicare beneficiaries, the general public, and to health professionals.
|
|
Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS
|
Other
|
FDA
|
NINDS
|
This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and FDA approval and licensure.
|
|
Mental Health Surveillance Study
|
Health Survey
|
SAMHSA
|
NIMH
|
Since 2008, the Substance Abuse and Mental Health Services Administration (SAMHSA) has produced national and state estimates of serious mental illness among adults using the National Survey on Drug Use and Health (NSDUH). The estimates are based on the Mental Health Surveillance Study (MHSS) which provides estimates of serious mental illness among adults aged 18 or older at both national and state levels. The MHSS builds upon established federal survey platforms in order to expand the NIMH research portfolio in population-based mental health studies. The purpose of the MHSS was to conduct additional calibration work on the survey data; to assess the feasibility of developing a longitudinal component for future surveys; and to produce reports related to mental health. In FY2013, NIMH participated in 23 data analysis activities related to the development of a population measure of Serious Mental Illness (SMI); mental illness correlates in adults and youth; disparities in mental health service use; suicidality in the general populations; and smoking among persons with mental illnesses.
|
|
Microphysiological Systems for Drug Efficacy and Toxicity Testing
|
Research Initiative
|
FDA
|
NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/ORWH
|
The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans.
|
|
Microsystems Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDDK, NINDS
|
The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund and participating NIH IC''s, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics.
|
|
Mobile Applications for Data Collection on Adverse Events of Medication or Device During Public Health Emergencies
|
Resource Development
|
FDA
|
NLM
|
The National Library of Medicine (NLM) and the U.S. Food and Drug Administration (FDA) established a partnership to explore the development, assessment, and utilization of mobile applications to disseminate and exchange scientific information and data concerning reported adverse events from the use of a medication or medical device approved under the Emergency Use Authorization in a public health emergency or disaster.
|
|
mPOWER mHealth Group
|
Research Initiative
|
CDC, CMS, FDA, HRSA, IHS
|
NINR, CIT, FIC, NCCAM, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR
|
Mobilizing Research supports the development, promotion, and dissemination of a wireless health research recruitment and data platform. In addition to being a primary data collection mechanism, the platform would be a data repository for both basic and applied health science, making validation and standardization of mobile health tools accessible.
|
|
Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CMS, FDA
|
NIBIB, NCI, NHLBI, NIA, NIAMS, NICHD, NIDCD, NIDCR, NINDS
|
The Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group (IWG), originally organized under the auspices of the Subcommittee on Biotechnology of the National Science and Technology Council (NSTC), was established in 2000 to provide a forum for federal agencies involved in tissue science and engineering to stay informed of each other''s activities and coordinate research efforts. Its five-year plan was renewed in 2002 and new Terms of Reference were introduced in 2007. The MATES group now works independently of NSTC and is comprised of many participating agencies. The principal purpose of the MATES IWG is to provide a platform across which member agencies can interact and exchange information on tissue engineering efficiently and effectively. It is the means by which Federal agencies involved in tissue engineering stay informed of each other''s activities and coordinate their efforts in a timely and efficient manner. The MATES IWG organized and co-chaired the opening symposium of the 2014 meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), held December 13-16, 2014. In addition, a new e-book is being planned by the MATES IWG, which will discuss federal coordination of TE/RM activities and goals. Authors will include reps from NIH and FDA.
|